you can't approve something that does not require FDA testing &/or approval
"Personally I never doubted the validity of the product Tollovid, it's just the company made all the wrong moves to get it approved for Covid and like I said in my earlier post...."
just where has Tollovid ever been validated - validated by whom - validated for what exactly...?
sorry but your above quote makes absolutely no sense to me whatsoever...
"it's just the company made all the wrong moves to get it approved for Covid"
maybe the intent was never to get something that did not require approval approved...
maybe the intent was to create an illusion that something was being created when in essence something else was going on...
if you can't figure out what that motive may have been - then nothing else I say will matter to you anyway...
cop a clue pal - its game over
the $$$ came and went and only the TOMDF SH's got fleeced AGAIN by Gerald Commissiong & Co.
IMHO there's a 99% rock solid chance that BK is the only thing left on the table at this point in the scam
TOMDF Corporate HQ's located at 40 Wall St which is a "We Works" cubicle rental:
SMH - can't make this stuff up folks...!
would you trust this man with your family's hard earned honest dollars...?
scam line-up of PR milestone deliverables - none of which ever got successfully delivered
Todos Medical Provides Corporate Update: Retooling to Focus on Long COVID Epidemic Sep 26, 2023 11:01am EDT
Todos Announces Notice of Allowance From USPTO for Patent Application Covering Use of Compositions In Tollovid™ and Tollovir™ Ingredients Aug 30, 2023 8:19am EDT
Todos Medical Enters Into Letter of Intent for Provista Diagnostics to License PCR-based Sepsis Diagnostic Test AcuSept LDT Rights From Acumen Diagnostics Mar. 28, 2023
Todos Medical Begins Trading on the OTC Pink Marketplace Mar. 27, 2023
Todos Medical Supports Long COVID Awareness Day Mar. 15, 2023
Todos Medical Enters Into Moratorium on Conversions Agreement With Convertible Note Holders Mar. 13, 2023
Todos Medical Initiates Validation Plan for PCR-based Avian Influenza A (H5N1, Bird Flu) Test at CLIA/CAP Testing Lab Provista Diagnostics Feb. 14, 2023
Todos Medical to Present at the RHK 2022 Disruptive Growth Conference Dec. 06, 2022
Todos Medical’s 3CL Pharma Awarded Oral and Poster Presentations at World Antiviral Congress 2022 Nov. 29, 2022
Todos Medical to Attend World Antiviral Congress Nov. 22, 2022
Todos Medical Enters Into Exclusive Worldwide Automated Retail Supply Agreement With Smart Automated Retail Network Nov. 16, 2022
Todos Medical Terminates Tollovid™ Products License & Distribution Agreement with T-Cell Protect Hellas S.A. Nov. 10, 2022
Todos Medical CLIA/CAP Lab Provista Submits Emergency Use Authorization Application for MonkeyPox PCR Test to US FDA Oct. 14, 2022
Todos Medical Announces Successful Pilot Launch of Suite of PCR Testing Services by CLIA/CAP Lab Provista Diagnostics Oct. 06, 2022
Todos Medical Receives Two Notices of Allowance from USPTO for AI-Based TBIA Pan-Cancer Blood Diagnostics Platform Sep. 30, 2022
Todos Medical Announces USPTO Trademark Notice of Allowance for 3CL Protease Biomarker Diagnostics TolloTest™ Sep. 27, 2022
Todos Medical Enters Into $50M Contract to Supply Tollovid™ and CBD Products to Retail Distributor Company Nerd Hemp Sep. 22, 2022
Todos Medical Announces NFL Hall of Famer Michael Irvin as Tollovid™ Sports Ambassador for #TolloUp Campaign Sep. 16, 2022
Todos Medical Announces Preprint of Long COVID Case Study Participant with Confirmed Microclot and Hyperactivated Platelets who Benefitted from Tollovid Sep. 15, 2022
Todos Medical & The Alchemist’s Kitchen to Host “Long COVID: An Integrated Approach” Event Benefitting Survivor Corps Sep. 13, 2022
Todos Medical’s 3CL Protease Inhibitor Supplement Tollovid™ Featured in Wellness Magazine Sep. 13, 2022
Todos Medical Partner NLC Pharma Assigns IP for Tollovir™, Tollovid™, and TolloTest™ into JV 3CL Pharma Sep. 12, 2022
Todos Medical CEO Discusses Long COVID Economic Impact with Moneta Advisory Managing Partner Marc LoPresti Sep. 09, 2022
Todos Medical Announce Kingcarlx as Brand Ambassador for the Tollovid #TolloUp Lifestyle Campaign Sep. 02, 2022
Todos Medical Establishes Botanical Supplement Manufacturing Capabilities to Support Tollovid Global Expansion and Initiates CBD-A Production Aug. 31, 2022
Todos Medical Expands COVID Onsite School Sample Collection to Include MonkeyPox Testing Aug. 29, 2022
Todos Medical Announces Saliva-Only MonkeyPox Testing at CLIA/CAP Clinical Lab Provista Diagnostics Aug. 26, 2022
Todos Medical Enrolls Female Long COVID Patient Unable to Secure Testing While Symptomatic for MonkeyPox into Provista Diagnostics Case Study Series Aug. 25, 2022
Todos Medical Initiates MonkeyPox Diagnostic Case Studies After Being Approached by 4 Patients, Including 3 Women Aug. 23, 2022
Todos Medical Announces Commercialization of Lesion and Saliva-Based MonkeyPox PCR Testing Aug. 22, 2022
Todos Medical Announces Preprint of Data from First 100 Participants in IRB-waived Market Research Study of Supplementation with Tollovid in Long COVID Aug. 19, 2022
Todos Medical Reports Pre-Print of Publication Detailing Tollovid Supplementation Following COVID-19 mRNA Vaccination in Long COVID Aug. 15, 2022
Todos Medical Completes Trial Design for Tollovid™ Long COVID Clinical Study in Adults Aug. 11, 2022
Todos Medical Announces PCR Validation of Wound and Respiratory Pathogen Panels at CLIA/CAP Lab Provista Diagnostics Aug. 10, 2022
Todos Medical Announces First Two Contracts for PCR-based MonkeyPox Testing at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics Aug. 08, 2022
Todos Medical Announces First Long COVID Clinic Laboratory Services Agreement for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics Aug. 05, 2022
Todos Medical Initiates Validation Plan for PCR-based MonkeyPox Test at CLIA/CAP Clinical Testing Laboratory Provista Diagnostics Aug. 03, 2022
Todos Medical Announces Preprint of Acute COVID-19 Paxlovid Rebound Rescued by Tollovid Aug. 01, 2022
Todos Medical Partners with Amerimmune Diagnostics on Long COVID Biomarker Panel Jul. 28, 2022
Todos Medical Announces Preprint of Chronic Long COVID Case Study #8 of Paxlovid® Treatment Followed by Tollovid™ Dietary Supplementation Jul. 22, 2022
Todos Medical Reports Case Study #7 in Acute and Long COVID Jul. 12, 2022
Todos Medical Announces Positive Biomarker Data from Phase 2 Trial of Tollovir in Hospitalized COVID-19 Patients Jun. 30, 2022
Todos Medical Releases Preliminary Data From IRB-Waived Tollovid® Market Research Study in Acute and Long COVID Jun. 23, 2022
Todos Medical Retains Moneta Advisory Partners as Strategic Advisors for National Exchange Listing and 3CL Pharma Spinoff Jun. 21, 2022
Todos Medical Completes Validation of 27 Pathogen UTI PCR Panel at Its CLIA/CAP Laboratory Provista Diagnostics Jun. 13, 2022
Todos Medical Reports Day 45 Update for Case Study #6 Jun. 10, 2022
Todos Medical Reports Day 28 Update for Case Study #5 with Erectile Dysfunction Jun. 07, 2022
Todos Medical Announces Enrollment Complete for Confirmatory Cohort of LymPro Alzheimer’s Blood Test Clinical Validation Trial vs. Amyloid PET Jun. 03, 2022
Todos Medical Reports Day 26 Update For Case Study #4 Jun. 01, 2022
Todos Medical to Present Final Data from the Tollovir Phase 2 Clinical Trial in Hospitalized COVID-19 Patients at the Personalized Medicine World Conference May 27, 2022
Todos Medical Reports Day 14 Update from Ongoing 30-Day Case Study of Paxlovid Rebound Patient May 06, 2022
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid® Max Strength Including 5 Day Dosing, 30 Day Dosing and 3CL Protease (3CLpro, Mpro, Nsp5) Inhibitor Claim May 02, 2022
Todos Medical Initiates IRB-Waived Tollovid Market Research Study and Announces 50% Price Reduction Until May 30th, 2022 Apr. 27, 2022
Todos Medical Appoints Philippe Goix as Chief Commercial Officer for Provista Diagnostics Apr. 21, 2022
Todos Medical Reports 2nd Long COVID Case Study and Launches Website for Physicians and Pediatricians to Indicate Interest in Participating in Tollovid Long COVID Clinical Study Apr. 20, 2022
Todos Medical Targets Athlete Support with Informed Sport Certification for Tollovid by LGC Group Apr. 19, 2022
Todos Medical Applauds White House Initiative on Long COVID and Announces New Tollovid® US FDA Certificate of Free Sale with Daily and Acute Dosing on the Label Apr. 06, 2022
Todos Medical Announces Positive 3CL Protease Inhibition In Vitro Data Against BA.1 and BA.2 Omicron SARS-CoV-2 Variants Apr. 04, 2022
Todos Medical Reports Case Study of Patient with Long COVID Mar. 31, 2022
Billy Blanks® Endorses Todos Medical’s Line of Tollovid® Products Mar. 28, 2022
Todos Medical Completes Acquisition of Key Assets and Intellectual Property from NLC Pharma Mar. 16, 2022
Todos Medical Appoints Greg Meiselbach as Vice President of Government Affairs Mar. 08, 2022
Todos Medical and NLC Pharma Announce Primary and Secondary Endpoints Met in NLC-V-01 Phase 2 Clinical Trial of Oral Antiviral 3CL Protease Inhibitor Tollovir™ in the Treatment of Hospitalized COVID-19 Patients Jan. 27, 2022
Todos Medical Announces Data Lock in Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients Jan. 24, 2022
Pepperdine University Hosts the 22nd Annual Celebrity Flag Football Challenge®, Presented by Todos Medical’s Tollovid® Jan. 19, 2022
Todos Medical Releases Videos of Recent CEO Interviews with Fox Business, NewsMax and Black News Channel on COVID Testing & Treatment Strategies Jan. 18, 2022
Todos Medical to Announce Topline Results from Tollovir™ Phase 2 Clinical Trial from the Treatment of Hospitalized COVID-19 Patients on January 27th, 2022 Jan. 12, 2022
Todos Medical CEO to Appear on Fox Business to Talk COVID Testing & Tollovir on Tuesday, January 11, 2022 and is Presenting at Biotech Showcase 2022 Jan. 10, 2022
Todos Medical Records Record Weekly COVID PCR Testing Volumes at Provista Dec. 27, 2021
Todos Medical CEO to Appear on Yahoo Finance Live! at 12:10PM EST with Akiko Fujita to Talk Pfizer’s Paxlovid Approval, Tollovir™ Phase 2 & COVID Testing Dec. 23, 2021
Todos Medical Announces New cPass Neutralizing Antibody Testing Reference Lab Agreement for CLIA/CAP Lab Provista with Physician Group in 40 States Dec. 22, 2021
Todos Medical Appoints Valentino Smith, MBA as Vice President of Marketing Dec. 20, 2021
Todos Medical Announces “Test & Tollovid®” Holiday Package for Atlanta Area at Provista Diagnostics Dec. 17, 2021
Todos Medical to Host Key Opinion Leader Webinar Entitled Tollovir™: a Potential Treatment for Covid-19 Dec. 16, 2021
Todos Medical Enters 90-Day Extension of Agreement with Convertible Note Holders on Moratorium on Conversions of Convertible Notes Dec. 13, 2021
Todos Medical Interview and Presentation on Benzinga's All Access Conference Live December 14th at 10:20 AM EST Dec. 10, 2021
Todos Medical Announces 2 New COVID-19 PCR Testing Reference Lab Agreements for CLIA/CAP Lab Provista Diagnostics Dec. 07, 2021
CEOs Presenting at the Emerging Growth Conference on December 8; Register Now Dec. 07, 2021
Todos Medical to Present at Upcoming Emerging Growth Conference Dec. 06, 2021
Todos Medical Announces All 31 Patients Enrolled to Date in Tollovir® Phase 2 Clinical Trial in Hospitalized COVID-19 Patients Have Completed Study Participation Dec. 02, 2021
Todos Medical Confirms SARS-CoV-2 PCR Test Kits Used at CLIA/CAP Lab Provista Diagnostics Detect Omicron Variant Nov. 30, 2021
Todos Medical Enters into Binding Agreement to Acquire All 3CL Protease Biology-Related Assets and Intellectual Property from NLC Pharma Nov. 29, 2021
Todos Medical Receives Purchase Order for 50,000 Bottles of Tollovid Daily from Its European Distribution Partner T-Cell Protect Hellas S.A for Initial Market Launch in Greece Nov. 22, 2021
Todos Medical Announces Completion of Enrollment for COVID-19 Oral Antiviral 3CLPro (Mpro) Inhibitor Tollovir Phase 2 Clinical Trial Interim Analysis in Severe and Critical Hospitalized Patients Nov. 19, 2021
Todos Medical Announces Tollovid® Products Exclusive License & Distribution Agreement with T-Cell Protect Hellas S.A. Covering 30 Countries in Europe Nov. 18, 2021
Todos Medical Announces Addition of Semi-Quantitative Titer Claims to the Emergency Use Authorization for the cPass Neutralizing Antibody Test Nov. 17, 2021
Todos Medical’s Provista Laboratory to Boost Top Line Through New Atlanta-based Reference Lab Agreement for COVID PCR, cPass Neutralizing Antibody & Respiratory Pathogen Panel Tests Nov. 16, 2021
Todos Medical Reports Third Quarter 2021 Business and Financial Results Nov. 15, 2021
Todos Medical Sees Significant Ramp Up in COVID PCR Testing Volume at Its Provista CLIA/CAP Lab with New Automation in Place Nov. 02, 2021
Todos Medical Announces 2nd Clinical Trial Site for Tollovir Phase 2 Clinical Trial for the Treatment of Hospitalized COVID-19 Patients Nov. 01, 2021
Todos Medical Announces Publication in Nature Neuroscience That Describes the Main Protease (3CL Protease) Causes Microvascular Brain Pathology Oct. 25, 2021
Todos Medical Announces Publication in Journal of Clinical Virology Highlighting Clinical Utility of cPass Semi-Quantitative Neutralizing Antibody Test in SARS-CoV-2 Risk Assessment Post-Vaccination or Recovery from Infection Oct. 21, 2021
Todos Medical to Conduct Webinar Highlighting the cPass SARS-COV-2 Neutralizing Antibody Test for AMDA, The Society for Post-Acute and Long-Term Care Medicine, on October 22, 2021 at 12:00 PM EDT Oct. 14, 2021
Todos Medical Announces Positive Data in Hospitalized and Outpatient Setting for TolloTest™, a Novel SARS-CoV-2 3CL Protease Biomarker Assay Oct. 06, 2021
Todos Medical Provides Update on COVID-19 Oral Antiviral 3CL Protease (Main Protease) Inhibitor Tollovir Clinical Development Program in Light of Molnupiravir Clinical Trial Data from Merck Oct. 04, 2021
Todos Medical Announces Positive Observational Trial Results for Oral Antiviral 3CL Protease (MPro) Inhibitor Tollovir® Sep. 30, 2021
Todos Medical Receives Approval by Amazon to Sell Immune Supplements Tollovid® & Tollovid Daily™ Sep. 27, 2021
Todos Medical Reports Second Quarter 2021 Financial Results Fri, Sep. 24, 2021
UPDATE: Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders Sep. 24, 2021
Todos Medical Launches Tollovid Daily™ via Subscription at MyTollovid.com Sep. 23, 2021
Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Oral Antiviral Drug Candidate Tollovir™ Sep. 20, 2021
Todos Medical Now Accepting Cryptocurrency for the Purchase of Tollovid® and Tollovid Daily™ Through Coinbase Commerce Sep. 17, 2021
Todos Medical Announces 90-Day Moratorium on Conversions of Convertible Notes and Lockup of Common Stock Sales with Convertible Note Holders Sep. 15, 2021
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of Combination COVID, Influenza A & B, RSV & hMPV Respiratory Panel Test Sep. 01, 2021
Todos Medical’s CLIA/CAP Lab Provista Completes Validation of High-Capacity SARS-CoV-2 Variant Testing Service Capable of Identifying Known Variants Aug. 26, 2021
Todos Medical’s CLIA/CAP Lab Provista Enters Into Reference Lab Agreement with Meadowlands Diagnostics to Provide cPass Neutralizing Antibody Blood Testing for Quantifying and Monitoring Key COVID-19 Immunity Biomarkers Aug. 24, 20211
Todos Medical Completes Validation of cPass Neutralizing Antibody Blood Test at Provista Diagnostics to Quantify and Monitor Key Biomarkers of COVID-19 Immunity Aug. 23, 2021
Todos Medical CEO to Appear on Fox Business Network Varney & Company Today at 11:40am to Discuss the Company’s Launch of cPass Neutralizing Antibody Testing for Monitoring COVID-19 Immunity Aug. 23, 2021
Update: Todos Medical Receives Trademark Notice of Allowance from USPTO for Its 3CL Protease Inhibitor Dietary Supplement Tollovid™ Aug. 05, 2021
Todos Medical Receipt Notice of Allowance from USPTO for 3CL Protease Inhibitor Dietary Supplement Tollovid™ Aug. 05, 2021
Todos Medical Makes Final Payment to Close Provista Diagnostics Acquisition Aug. 02, 2021
Todos Medical Retains CRO for COVID-19 Outpatient and Inpatient Phase 2/3 Clinical Trials for Oral Antiviral 3CL Protease Inhibitor Tollovir Jul. 28, 2021
Todos Medical Receives New FDA Certificate of Free Sale for Tollovid Daily™ Including 3CL Protease Inhibitor Claim Jul. 22, 2021
Todos Medical to Launch EUA Authorized cPass SARS-CoV-2 Neutralizing Antibody Kit Through Agreement with Fosun Pharma Jul. 19, 2021
Todos Medical Appoints Ilanit Halperin, CPA as Corporate Controller Jul. 07, 2021
Todos Medical Receives FDA Certificate of Free Sale for New 5-Day Tollovid Dosing Regimen May 04, 2021
Todos Medical Launches Phase 2 Clinical Trial of Its Antiviral 3CL Protease Inhibitor NLC-V-01 (Tollovir) in Hospitalized COVID-19 Patients Apr. 19, 2021
Todos Medical Receives Notice of Allowance from European Patent Office for Patent Application Covering Diagnosis of Cancer Using Proprietary Artificial Intelligence TBIA Immune Profiling Platform Apr. 08, 2021
Todos Medical Completes Automation Equipment Installation and Training for Meadowlands Diagnostics Apr. 01, 2021
Todos Medical Enters Into Distribution Partnership with Osang Healthcare for the GeneFinder Plus™ COVID-19 Plus RealAMP Kit in the United States Mar. 30, 2021
Todos Medical Completes Automation Equipment Installation and Training for a Laboratory Client in Brooklyn, NY Mar. 29, 2021
Todos Medical Enters Into Automation and Reagent Supply Agreement with MAJL Diagnostics Mar. 23, 2021
Todos Medical Announces $7.2M in Sales for February 2021, a 38% Month Over Month Increase From Sales of $5.2M in January 2021 Mar. 12, 2021
Todos Medical Applauds Senate and House Passage of the American Recovery Act Mar. 11, 2021
Todos Medical Announces Strategic Investment by Yozma Group Korea Jan. 25, 2021
Todos Medical Announces $4.8 Million in Sales for December 2020, a 50% Month Over Month Increase in Sales from November 2020 Jan. 11, 2021
Todos Medical Announces Agreement to Supply Natural Wellness Clinics with COVID-19 Testing Products to Support Initiatives in the Commonwealth of Kentucky Dec. 23, 2020
Aditxt Signs Distribution Agreement with Todos Medical Ltd. For AditxtScore™ for COVID-19 Immune Monitoring Service Dec. 14, 2020
Todos Medical Announces Commercial Launch of Proprietary 3CL Protease Inhibitor Dietary Supplement Tollovid™ at The Alchemist’s Kitchen Dec. 07, 2020
Todos Medical Announces $3.2 Million in Sales for November 2020, a 269% Increase Sequential Month over Month Sales Growth from October 2020 Dec. 02, 2020
Todos Medical Provides Strategic Outlook Dec. 01, 2020
Todos Medical Completes Installation of Lab Automation Equipment at Wisconsin Lab Client to Support COVID-19 PCR Testing Nov. 24, 2020
Todos Medical Announces Positive In Vitro Data for Tollovid™ Confirming 3CL Protease Inhibition Mechanism of Action Nov. 20, 2020
Todos Medical Announces Positive Initial Clinical Proof-of-Concept Data for a Rapid SARS-CoV-2 3CL Protease Detection Assay Nov. 18, 2020
Todos Medical Announces Clinical Validation and National CLIA Certification for MOTO+PARA Mobile High Complexity Labs Nov. 17, 2020
Todos Medical Announces $867,000 in Sales for October 2020 Nov. 12, 2020
Todos Medical Trademarks Tollovid for Dietary Supplement NLC-001 and Enters Into Private Label & Distribution Agreement With The Alchemists Kitchen Oct. 29, 2020
Todos Medical Announces Instrument Validation Complete at MOTO+PARA Mobile Lab Oct. 26, 2020
Todos Medical Announces Distribution Agreement with Adial Pharmaceuticals to Market the FDA, EUA Authorized, Assure/FaStep Point-of-Care Covid-19 Antibody Tests Oct. 22, 2020
Todos Medical Receives Notices of Allowance From the European Patent Office Covering Use of TBIA Cancer Platform to Detect Benign Colon Cancer Oct. 20, 2020
Todos Medical Reports $2.0 Million in Revenue for the Third Quarter of 2020 Oct. 13, 2020
Todos Medical Enters into Exclusive COVID-19 Testing Supply Agreement with MOTO+PARA’s National Mobile CLIA Lab Partner Integrated Health Oct. 07, 2020
Todos Medical Enters into Exclusive Branding and Distribution Agreement with Melbourne Biotech for 96 and 384 Well RT-PCR Machines in the United States Sep. 30, 2020
Todos Medical Enters Into COVID-19 PCR Testing Implementation and Equipment Financing Partnership with AID Genomics Sep. 25, 2020
Todos Medical Expands Existing Contract for COVID-19 PCR Testing Equipment & Supplies with Wisconsin-based Laboratory to $47.5 Million Sep. 22, 2020
Todos Medical CEO Releases Letter to Shareholders Sep. 18, 2020
3CL Protease Inhibitor NLC-001 Added to COVID-19-focused Joint Venture Between Todos Medical and NLC Pharma Sep. 17, 2020
Todos Medical Expands Partnership with Care G.B. Plus for Proprietary TBIA Cancer Tests to Include Europe, Israel and Africa Sep. 16, 2020
Todos Medical Announces Commercial Launch of Todos Branded COVID-19 qPCR Test Kits in the United States Sep. 11, 2020
Todos Medical Announces August Sales of $1,190,000, Up 100% Compared with July Sep. 03, 2020
Todos Medical Enters Into Partnership With Pangea for COVID-19 Testing and Contact Tracing Sep. 02, 2020
Todos Medical Announces $23,760,000 Contract for COVID-19 PCR Testing Equipment & Supplies With Wisconsin-based Laboratory Aug. 31, 2020
Todos Medical to Present at The LD 500 Virtual Conference Aug. 31, 2020
Todos Medical Announces $4,500,000 Contract for COVID-19 PCR Testing Equipment & Supplies with New York-based Laboratory Aug. 27, 2020
Todos Medical Appoints Marsha Fontanive as VP of Sales and Chris Gross as VP of Sales Operations Aug. 25, 2020
Todos Medical Announces $1.2 Million Contract for COVID-19 PCR Testing Equipment & Supplies with Texas-based Laboratory Aug. 24, 2020
Todos Medical Announces $6,000,000 Contract for COVID-19 PCR Testing Equipment & Supplies with New York-based Laboratory Aug. 21, 2020
Todos Medical Announces Positive Proof-of-Concept Data for Novel 10-Minute Point-of-Care Saliva-based Test Detecting Active SARS-CoV-2 Infection Aug. 17, 2020
Todos Medical Acquires Distribution Rights to SARS-CoV-2 Rapid Point-of-Care Antigen Test and Rapid Point-of-Care PCR Test Aug. 14, 2020
Todos Medical Announces July Sales of COVID-19 Tests Aug. 07, 2020
Todos Medical Announces Common Stock Purchase Agreement with Lincoln Park Capital Fund, LLC Aug. 06, 2020
Todos Medical Appoints Dr. Jorge Leon as Consulting Chief Medical and Scientific Officer of Infectious Disease and Oncology Aug. 04, 2020
Pathnova Laboratories (PATHNOVA) Enters into Partnership to Commercialize Todos Medicals COVID-19 and Breast Cancer Tests in Singapore Aug. 03, 2020
Todos Medical Completes Acquisition of Breakthrough Diagnostics, Gains Full Rights to the Alzheimer’s Blood Diagnostic LymPro™ Test from Amarantus Jul. 28, 2020
Todos Medical Announces SARS-nCoV-19 Testing Kit Contract with NJ-Based Best Supply Clinical Laboratory Jul. 27, 2020
Todos Medical Expands Management Team and Advisory Board Jul. 20, 2020
Todos Medical Announces ANVISA Authorization in Brazil for 3D Med qPCR Kits and ANDis Extraction S Jul. 16, 2020
Todos Medical Releases Letter to Shareholders Feb 07, 2020 9:15am EST
Todos Medical Enters into Exclusive Option Agreement to Acquire Provista Diagnostics and Announces Management Changes Jan 09, 2020 8:00am EST
Todos To Present At Upcoming 12th Annual LD Micro Main Event Dec 06, 2019 7:29am EST
Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer’s Blood Test Relationship with Amyloid PET Nov 14, 2019 11:02am EST
Todos Medical to Present at Dawson James Small Cap Growth Conference Oct 24, 2019 9:25am EDT
Todos Medical and Orot+ Announce First Patient Enrolled in Pre-Commercial Launch Preparations of TM-B1 and TM-B2 Breast Cancer Blood Screening Tests in Europe Sep 24, 2019 9:14am EDT
Todos Medical Signs Binding Term Sheet with HWH World for Network Marketing of Blood Tests for the Early Detection of Breast Cancer Sep 13, 2019 7:30am EDT
Todos Medical Enters into MOU to Expand Existing Early Detection Breast Cancer Blood Test Distribution Partnership with Orot+ into Japan Sep 03, 2019 1:29pm EDT
Todos Medical Appoints Dr. Jorge Leon as Medical Advisor Aug 06, 2019 7:00am EDT
Todos Medical Announces Positive Alzheimer's Biomarker Clinical Data from LymPro vs. Amyloid PET Interim Analysis Jul 15, 2019 7:00am EDT
Todos Medical CEO Presented Corporate Update And Roadmap at The LD Micro Conference Jun 17, 2019 8:30am EDT
Todos Medical Announces Positive Clinical Trial Data for Breast Cancer Blood Test TM-B1 in Dense Breasts Jun 03, 2019 8:00am EDT
Todos Medical Exercises Option to Acquire Remaining 80.01% of Breakthrough Diagnostics from Amarantus After Review of Alzheimer's Blood Test Data May 28, 2019 8:57am EDT
Todos Medical Receives Approval from Israeli Ministry of Health (AMAR) to Market and Sell its Breast Cancer Screens in Israel May 23, 2019 8:00am EDT
Todos Medical Enters Exclusive Distribution Agreement with Care G.B. Plus, Ltd. for its Breast Cancer Screening Tests in Israel May 21, 2019 8:00am EDT
Todos Medical Announces Voting Results from 2019 Annual Shareholder Meeting May 03, 2019 8:52am EDT
Todos Medical Receives Notice of Allowance from the USPTO Covering the Early Diagnosis of Lung Cancer Using the Todos Biochemical Infrared Analysis (TBIA) May 01, 2019 8:00am EDT
Todos Medical Enters Into Definitive Agreement With Orot+ for Exclusive Distribution Rights of its Breast Cancer Screening Tests in 2 European Countries Apr 15, 2019 8:00am EDT
Todos and Amarantus Announce Completion of LymPro PET 1 Study by Leipzig University for Alzheimer’s Blood Diagnostic LymPro Test 2.0 Apr 08, 2019 7:30am EDT
Todos Medical to Present at Two Upcoming Investor Conferences Mar 28, 2019 8:00am EDT
Todos Medical Appoints Dr. Colin Bier to Its Board of Directors Mar 27, 2019 8:00am EDT
Todos Medical Raises $1,350,500 In Funding and Finalizes Joint Venture Agreement with Amarantus Bioscience Feb 28, 2019 9:30am EST
Todos Medical Presents Encouraging Scientific Abstract at the San Antonio Breast Cancer Symposium (SABCS) Dec 06, 2018 4:00pm EST
Todos Medical Enters into Joint Venture Agreement with Amarantus to develop Alzheimer’s Blood Diagnostic LymPro Test 2.0 Dec 03, 2018 8:30am EST
Todos Medical to Present Scientific Abstract at the Upcoming San Antonio Breast Cancer Symposium (SABCS) Nov 29, 2018 8:30am EST
Todos Medical, Ltd. Announces Additional Patent Issuance Covering the Use of IR Spectrum of Blood Plasma For Indicating the Presence of Breast Cancer Oct 17, 2018 8:30am EDT
Todos Medical, Ltd. Signs Non-Binding Memorandum of Understanding with Orot+ for Distribution Rights of its Breast Cancer Screening Tests in Romania and Austria Sep 13, 2018 8:30am EDT
Todos Medical, Ltd. Appoints Herman Weiss, MD MBA as New Chief Executive Officer Jul 31, 2018 4:03pm EDT
Todos Medical reports on results of clinical trials for its blood test for breast cancer screening (TM - B1) conducted at Kaplan Hospital in Rehovot, Israel Mar 22, 2018 8:00am EDT
Todos Medical initiates clinical trial of its blood test for breast cancer in Kaplan Hospital, Rehovot, Israel for subjects undergoing breast cancer screening Mar 05, 2018 8:00am EST
U.S. Patent and Trademark Office has granted to Todos Medical two additional patents Feb 12, 2018 8:00am EST
Mr. David Ben Naim, CPA, MBA Joins Todos Medical as Chief Financial Officer Feb 06, 2018 8:00am EST
Todos Medical Appoints Dr. Meir Silver as Vice President of Clinical Research and Regulatory Affairs Aug 29, 2017 8:30am EDT
but hey, here's to you and the TOMDF Boiler Room Pump Boi's:
